Market News & Trends
LIXTE Biotechnology Enters Exclusive Immune Oncology Patent License Agreement With NINDS & NCI
LIXTE Biotechnology Holdings, Inc. recently announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National…
Tenaya Therapeutics Announces Preclinical HDAC6 Inhibitor Data for Heart Failure With Preserved Ejection Fraction
Tenaya Therapeutics, Inc. recently announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the…
Curia Appoints New Vice President, Biologics
Curia recently announced it has appointed Steve Lavezoli as Vice President of Biologics effective February 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery,…
Jubilant HollisterStier Opens Third Manufacturing Line
Jubilant HollisterStier recently celebrated the opening of its third sterile fill finish manufacturing line and broke ground on the next phase of its facility expansion in Spokane, WA…..
MAIA Biotechnology Completes Enrollment in Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. recently announced enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor…
Tarsus Announces Positive Topline Results From Phase 2a Proof-of-Concept Trial Evaluating TP-05 for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis….
Rigel Pharmaceuticals Acquires US Rights to GAVRETO
Rigel Pharmaceuticals, Inc. recently announced it has entered into a definitive agreement to acquire the US rights to GAVRETO (pralsetinib) from Blueprint Medicines Corporation. GAVRETO…
Avenue Therapeutics Announces First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Avenue Therapeutics, Inc. recently announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the…
Aptar Digital Health Announces Acquisition of Healint to Reinforce Digital Health Portfolio & Drive Future Growth
Aptar Digital Health recently announced it has acquired Healint, a digital health company recognized for their virtual clinical studies, real-world evidence and patient registries platform,…
Polpharma Biologics’ Investigational Biosimilar Shows PK/PD Comparability to Inflammatory Bowel Disease Blockbuster Entyvio
Polpharma Biologics recently announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio (vedolizumab). Results…
Cresset Announces Global Collaboration With Enamine on New Virtual Screening Drug Discovery Technology
Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative….
Eton Pharmaceuticals Awarded US Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals recently announced the United States Patent and Trademark Office (USPTO) has granted the company’s US Patent Application No. 18/113,458, which covers the….
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
Vaccinex, Inc. recently announced it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug…
Dyadic Advances Collaboration With Israel Institute for Biological Research Targeting Bio-Threats & Emerging Disease Solutions
Dyadic International, Inc. and Israel Institute for Biological Research (IIBR) recently announced it has advanced its collaboration with IIBR and its commercial arm Life Science…
XOMA Enters Agreement to Acquire Kinnate Biopharma
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio….
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease; Advances Program Into Late Research
Voyager Therapeutics, Inc. recently announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s…
Evonik Partners With University of Mainz to Commercialize New Class of PEG Lipids for Nucleic Acid Delivery
Evonik and the University of Mainz have signed a license agreement to commercialize randomized polyethylene glycols (rPEGs), a new class of PEGs. Evonik intends to use….
Monopar Receives Clearance to Proceed With First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Monopar Therapeutics Inc. recently announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its…
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Immuneering Corporation recently announced the US FDA granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal…
Mestag Therapeutics Enlists Leading Cancer Biology & Immunology Advisors to Support Clinical Development of its Lead Oncology Program
Mestag Therapeutics recently announced the appointments of additional distinguished, world-leading advisors to guide the development of its lead program M300, a first-in-class antibody program designed…
